Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 21 of 21 entries
View as:

A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.

Phase: N/A Priority: Normal
NCT ID: NCT01955564 Org: User:
Start: 06/30/13 End: 02/28/15 Due: 02/28/16

A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT01211587 Org: User:
Start: 09/30/10 End: - Due: -

Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients

Phase: N/A Priority: Normal
NCT ID: NCT00865579 Org: User:
Start: 04/30/09 End: 06/30/12 Due: 06/30/13

A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics

Phase: N/A Priority: Normal
NCT ID: NCT01026428 Org: User:
Start: 09/30/09 End: - Due: -

Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa

Phase: N/A Priority: Normal
NCT ID: NCT00627640 Org: User:
Start: 02/28/09 End: 03/31/12 Due: 03/31/13

Efficacy and Safety of Ralfinamide in Patients With Chronic Neuropathic Low Back Pain

Phase: N/A Priority: Normal
NCT ID: NCT01019824 Org: User:
Start: 03/20/09 End: 08/09/11 Due: 08/09/12

A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics

Phase: N/A Priority: Normal
NCT ID: NCT01027169 Org: User:
Start: 04/30/09 End: - Due: -

Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01113320 Org: User:
Start: 04/30/10 End: 01/31/12 Due: 01/31/13

A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging

Phase: N/A Priority: Normal
NCT ID: NCT01264861 Org: User:
Start: 03/31/11 End: 01/24/12 Due: 01/24/13

Safinamide Renal Impairment Trial

Phase: N/A Priority: Normal
NCT ID: NCT01374113 Org: User:
Start: 06/30/11 End: - Due: -

Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist

Phase: N/A Priority: Normal
NCT ID: NCT00643045 Org: User:
Start: 12/31/04 End: 07/31/07 Due: 07/31/08

A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT02624167 Org: User:
Start: 12/31/15 End: 01/31/17 Due: 01/31/18

Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms

Phase: N/A Priority: Normal
NCT ID: NCT02790034 Org: User:
Start: 10/26/16 End: 05/04/20 Due: 05/04/21

Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT01187966 Org: User:
Start: 01/31/07 End: 02/28/09 Due: 02/28/10

MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)

Phase: N/A Priority: Normal
NCT ID: NCT01028586 Org: User:
Start: 10/31/09 End: - Due: -

Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT04461119 Org: User:
Start: 06/16/20 End: 03/13/21 Due: 03/13/22

Phase II Dose Titration Study in Patients With Neuropathic Pain

Phase: N/A Priority: Normal
NCT ID: NCT00736151 Org: User:
Start: 05/31/04 End: - Due: -

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist

Phase: N/A Priority: Normal
NCT ID: NCT00605683 Org: User:
Start: 11/30/07 End: 03/31/12 Due: 03/31/13

An Open Label, Single-Dose Study of 14C-NW-3509 in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03446274 Org: User:
Start: 04/02/18 End: 06/30/18 Due: 06/30/19

Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)

Phase: N/A Priority: Normal
NCT ID: NCT00642889 Org: User:
Start: 06/30/05 End: 07/31/07 Due: 07/31/08

18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD

Phase: N/A Priority: Normal
NCT ID: NCT01286935 Org: User:
Start: 08/31/07 End: 08/31/10 Due: 08/31/11